ProShares Ultra NASDAQ Biotechnology(BIB · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$82.82
- 52-Week Range
- $44.20 – $90.91
- YTD
- +4.00%
- IV Rank (30D)
- 12.69
- Straddle Price
- $9.80
- P/C Vol Ratio
- 0.50
Info
ProShares Ultra NASDAQ Biotechnology (BIB) ETF
- Exchange
- XNAS
- Inception
- 2010-04-06
- Has Options
- Yes
ETF Profile
holdings as of 2026-06-12
Holdings
261
AUM
$148.9M
Provider
ProShares
Inception
2010-04-06
Exchange
XNAS
Data As Of
2026-06-12
Expense Ratio
—
Dividend Yield
0.60%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-25 | 2026-03-31 | $0.0071 | CD |
| 2025-12-24 | 2025-12-31 | $0.1346 | CD |
| 2025-09-24 | 2025-09-30 | $0.1805 | CD |
| 2025-06-25 | 2025-07-01 | $0.1706 | CD |
| 2025-03-26 | 2025-04-01 | $0.1309 | CD |
| 2024-12-23 | 2024-12-31 | $0.3964 | CD |
Asset Allocation
Top Holdings
top 50 of 261 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | NASDAQ Bio Index SWAP BNP Paribas | 16.39% | Derivative | — |
| — | NASDAQ Biotechnology Index SWAP Citibank NA | 14.06% | Derivative | — |
| — | NASDAQ Biotechnology Index SWAP Bank of America NA | 12.24% | Derivative | — |
| — | NASDAQ Biotechnology Index SWAP Goldman Sachs International | 10.53% | Derivative | — |
| — | NASDAQ Biotechnology Index SWAP Societe Generale | 10.03% | Derivative | — |
| IQMM | PROSHARES GENIUS MNY MKT ETF | 3.36% | Equity (US) | — |
| — | NASDAQ Biotechnology Index SWAP UBS AG | 2.53% | Derivative | — |
| AMGN | AMGEN INC | 2.34% | Equity (US) | — |
| VRTX | VERTEX PHARMACEUTICALS INC | 2.29% | Equity (US) | — |
| GILD | GILEAD SCIENCES INC | 2.14% | Equity (US) | — |
| REGN | REGENERON PHARMACEUTICALS | 1.58% | Equity (US) | — |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 0.93% | Equity (US) | — |
| RVMD | REVOLUTION MEDICINES INC | 0.76% | Equity (US) | — |
| BIIB | BIOGEN INC | 0.73% | Equity (US) | — |
| ARGX | ARGENX SE - ADR | 0.63% | Equity (US) | — |
| ILMN | ILLUMINA INC | 0.61% | Equity (US) | — |
| UTHR | UNITED THERAPEUTICS CORP | 0.59% | Equity (US) | — |
| RPRX | ROYALTY PHARMA PLC- CL A | 0.58% | Equity (US) | — |
| INCY | INCYTE CORP | 0.54% | Equity (US) | — |
| ROIV | ROIVANT SCIENCES LTD | 0.53% | Equity (US) | — |
| INSM | INSMED INC | 0.52% | Equity (US) | — |
| MRNA | MODERNA INC | 0.49% | Equity (US) | — |
| VTRS | VIATRIS INC | 0.47% | Equity (US) | — |
| GH | GUARDANT HEALTH INC | 0.43% | Equity (US) | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | 0.40% | Equity (US) | — |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 0.35% | Equity (US) | — |
| EXEL | EXELIXIS INC | 0.34% | Equity (US) | — |
| ASND | ASCENDIS PHARMA A/S | 0.33% | Equity (US) | — |
| MEDP | MEDPACE HOLDINGS INC | 0.33% | Equity (US) | — |
| AXSM | AXSOME THERAPEUTICS INC | 0.32% | Equity (US) | — |
| BBIO | BRIDGEBIO PHARMA INC | 0.32% | Equity (US) | — |
| IONS | IONIS PHARMACEUTICALS INC | 0.30% | Equity (US) | — |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 0.27% | Equity (US) | — |
| SMMT | SUMMIT THERAPEUTICS INC | 0.27% | Equity (US) | — |
| SNY | SANOFI-ADR | 0.27% | Equity (US) | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 0.27% | Equity (US) | — |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 0.26% | Equity (US) | — |
| BNTX | BIONTECH SE-ADR | 0.26% | Equity (US) | — |
| KRYS | KRYSTAL BIOTECH INC | 0.23% | Equity (US) | — |
| NUVL | NUVALENT INC-A | 0.22% | Equity (US) | — |
| CYTK | CYTOKINETICS INC | 0.21% | Equity (US) | — |
| ONC | BEONE MEDICINES LTD-ADR | 0.21% | Equity (US) | — |
| TEM | TEMPUS AI INC-CL A | 0.21% | Equity (US) | — |
| HALO | HALOZYME THERAPEUTICS INC | 0.20% | Equity (US) | — |
| PRAX | PRAXIS PRECISION MEDICINES I | 0.18% | Equity (US) | — |
| ALKS | ALKERMES PLC | 0.18% | Equity (US) | — |
| IBRX | IMMUNITYBIO INC | 0.18% | Equity (US) | — |
| KYMR | KYMERA THERAPEUTICS INC | 0.17% | Equity (US) | — |
| PTGX | PROTAGONIST THERAPEUTICS INC | 0.17% | Equity (US) | — |
| IMVT | IMMUNOVANT INC | 0.17% | Equity (US) | — |
Geographic Breakdown
Fund Holdings
ProShares Ultra Nasdaq Biotechnology ·
NPORT-P period 2026-05-31
(filed 2026-04-24)
Net assets:
$92M
· 278 total positions
· equity 67.47%
· non-equity 24.02%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | Gilead Sciences, Inc. | 6.48% | $5.9M |
| 2 | Vertex Pharmaceuticals, Inc. | Vertex Pharmaceuticals, Inc. | 6.27% | $5.8M |
| 3 | Amgen, Inc. | Amgen, Inc. | 6.15% | $5.6M |
| 4 | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. | 4.06% | $3.7M |
| 5 | Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals, Inc. | 2.21% | $2.0M |
| 6 | Insmed, Inc. | Insmed, Inc. | 1.60% | $1.5M |
| 7 | Biogen, Inc. | Biogen, Inc. | 1.42% | $1.3M |
| 8 | Argenx SE | Argenx SE | 1.12% | $1.0M |
| 9 | United Therapeutics Corp. | United Therapeutics Corp. | 1.09% | $1.0M |
| 10 | Moderna, Inc. | Moderna, Inc. | 1.05% | $966349 |
| 11 | Illumina, Inc. | Illumina, Inc. | 1.03% | $948615 |
| 12 | Roivant Sciences Ltd. | Roivant Sciences Ltd. | 1.01% | $929379 |
| 13 | Incyte Corp. | Incyte Corp. | 1.00% | $918013 |
| 14 | Royalty Pharma plc, Class A | Royalty Pharma plc | 0.99% | $911677 |
| 15 | Revolution Medicines, Inc. | Revolution Medicines, Inc. | 0.99% | $910733 |
| 16 | Viatris, Inc. | Viatris, Inc. | 0.87% | $794022 |
| 17 | Ascendis Pharma A/S | Ascendis Pharma A/S | 0.72% | $661972 |
| 18 | Neurocrine Biosciences, Inc. | Neurocrine Biosciences, Inc. | 0.66% | $608879 |
| 19 | Ionis Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. | 0.66% | $606921 |
| 20 | Sanofi SA | Sanofi SA | 0.65% | $594577 |
| 21 | Bridgebio Pharma, Inc. | Bridgebio Pharma, Inc. | 0.64% | $591473 |
| 22 | Medpace Holdings, Inc. | Medpace Holdings, Inc. | 0.64% | $587740 |
| 23 | Summit Therapeutics, Inc. | Summit Therapeutics, Inc. | 0.62% | $570281 |
| 24 | Guardant Health, Inc. | Guardant Health, Inc. | 0.61% | $560959 |
| 25 | BioMarin Pharmaceutical, Inc. | BioMarin Pharmaceutical, Inc. | 0.60% | $547607 |
Showing top 25 of 261 equity holdings.
Non-equity holdings
— 17 positions,
24.02% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Derivative (equity) | 16.51% | $15.1M | 6 |
| Repurchase agreement | 5.69% | $5.2M | 9 |
| Short-term investment | 1.81% | $1.7M | 1 |
| Other | 0.00% | $0 | 1 |
Daily issuer data also available
(2026-06-13)
via ETF Constituents
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +4.11% | 16 |
| Feb | +0.08% | 16 |
| Mar | -1.34% | 16 |
| Apr | +1.09% | 17 |
| May | +1.11% | 17 |
| Jun | +3.22% | 17 |
| Jul | +6.37% | 16 |
| Aug | -0.42% | 16 |
| Sep | -1.16% | 16 |
| Oct | -0.57% | 16 |
| Nov | +8.60% | 16 |
| Dec | -0.89% | 16 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $80.94
SMA 50: $82.73
SMA 200: $76.94
Current: $82.65
EMA 12: $81.09
EMA 26: $81.51
MACD: -0.4253 | Signal: 0.1071
BEARISH
ADX (14): 9.81
RANGE
+DI: 23.59
−DI: 24.49
Momentum Oscillators
RSI (14): 51.96
NEUTRAL
Stoch %K: 53.97
Stoch %D: 46.07
Williams %R: -27.95
Volume & Volatility
BB Upper: $85.63
BB Lower: $76.26
NEUTRAL
OBV: 401,023
Vol SMA 20: 5,895
Vol ROC: 101.32%
ATR: $3.05
True Range: $1.62
HV 20: 54.7%
HV 30: 50.2%
HV 60: 48.8%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:07.111000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 12.69
- IV Rank (7D)
- 66.6
- Avg IV
- 50.3%
- Straddle (30D)
- $9.80
- Straddle (7D)
- $4.60
- P/C Volume
- 0.50
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.75
- Correlation (SPY)
- 53.2%
- R²
- 0.28
- Ann. Volatility
- 40.5%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|